<- Go Home
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Market Cap
CHF 240.6B
Volume
1.2M
Cash and Equivalents
CHF 7.6B
EBITDA
CHF 23.4B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CHF 47.5B
Profit Margin
74.79%
52 Week High
CHF 313.80
52 Week Low
CHF 231.90
Dividend
3.46%
Price / Book Value
7.79
Price / Earnings
23.88
Price / Tangible Book Value
51.40
Enterprise Value
CHF 267.6B
Enterprise Value / EBITDA
11.29
Operating Income
CHF 20.3B
Return on Equity
31.32%
Return on Assets
13.30
Cash and Short Term Investments
CHF 12.0B
Debt
CHF 34.6B
Equity
CHF 33.0B
Revenue
CHF 63.5B
Unlevered FCF
CHF 12.5B
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium